Imatinib
This oral targeted cancer therapy works by inhibiting specific tyrosine kinase enzymes, particularly BCR-ABL, the abnormal protein produced by the Philadelphia chromosome in chronic myeloid leukemia (CML). It was a breakthrough in cancer treatment and is also used for gastrointestinal stromal tumors (GISTs) and other cancers driven by specific kinase mutations. It transformed CML from a frequently fatal disease to one often managed long-term.
Molekularmasse
493,6030 g/mol
LogP
3,50
TPSA
86,30 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Arzneimittelklassen
Wirkmechanismus
Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.
2D-Struktur
Cite this structure
Embed this structure
SMILES
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
InChI
InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
Molecular Formula
C29H31N7O
HBD / HBA
2 / 7
Rotierbare Bindungen
7
Schwere Atome
37
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This oral targeted cancer therapy works by inhibiting specific tyrosine kinase enzymes, particularly BCR-ABL, the abnormal protein produced by the Philadelphia chromosome in chronic myeloid leukemia (CML). It was a breakthrough in cancer treatment and is also used for gastrointestinal stromal tumors (GISTs) and other cancers driven by specific kinase mutations. It transformed CML from a frequently fatal disease to one often managed long-term.
Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.
Key pharmacokinetic parameters for Imatinib: Half-life: 18 hours.
Yes, Imatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL941. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5291. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="imatinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/imatinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/imatinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/imatinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="imatinib"></drugfyi-drug>